Previous 10 | Next 10 |
Mustang Bio (NASDAQ: MBIO ) prices public offering of 10,769,231 common shares at $3.25/share, for expected gross proceeds of $35M. More news on: Mustang Bio, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
TDH Holdings (NASDAQ: PETZ ) -35% . More news on: TDH Holdings, Inc., Genius Brands International, Inc., Hertz Global Holdings, Inc., Stocks on the move, Read more ...
Gainers: JFIN +15% . FTSI +11.1% . JACK +8.4% . ASNA +6.4% . DUO +5.7% . More news on: Jiayin Group Inc., FTS International, Inc., Jack in the Box Inc., Stocks on the move, , Read more ...
WORCESTER, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, sol...
Gainers: Mmtec (NASDAQ: MTC ) +83% . More news on: Mmtec, Inc., Luckin Coffee Inc., Mitcham Industries, Inc., Stocks on the move, , Read more ...
WORCESTER, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, soli...
Mustang Bio (NASDAQ: MBIO ): Q1 Non-GAAP EPS of -$0.07 beats by $0.24 ; GAAP EPS of -$0.19 beats by $0.12 . More news on: Mustang Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WORCESTER, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, soli...
The European Medicines Agency (EMA) has granted Advanced Therapy Medicinal Product (ATMP) classification to Mustang Bio's (NASDAQ: MBIO ) MB-107, a lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease. More news on: Must...
NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumo...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficul...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...